Recent Updates
Recently added Catalysts
ABBV Positive Sentiment

DISCO Pharmaceuticals Announces Strategic Collaboration with AbbVie to Advance Next-Generation AND-Gated Bispecific Therapeutics for Solid Tumors

Key Takeaway: DISCO Pharmaceuticals has partnered with AbbVie to develop AND-gated bispecific therapeutics for solid tumors. The collaboration includes a $40 million upfront payment and potential milestone payments totaling $2.5 billion. This partnership aims to leverage DISCO's surfaceome mapping platform to create targeted therapies that spare healthy tissue.
Price reaction · baseline $286.01 (2026-11-18 close) · hit pre-market · clean, no other ABBV news in the window
day 0 close · peak
-0.9%

Market Sentiment Analysis

POSITIVE FACTORS

  • Collaboration aims to advance precision medicines.
  • DISCO to receive $40 million upfront.
  • Potential for up to $2.5 billion in milestone payments.
  • AND-gated approach may improve treatment specificity.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+46%
120-day peak, hindsight
Typical move
1.3%
average across 15 past catalysts
Lead asset
Telisotuzumab Adizutecan
Phase 3 · Non-Squamous Non-Small Cell Lung Cancer

Full Press Release Details

• The collaboration leverages DISCO’s proprietary DISCOtech® surfaceome mapping platform and AND-gated bispecific discovery approach together with AbbVie’s global oncology research and development expertise to identify and potentially advance highly selective AND-gated bispecific therapeutics.
• Upon successful completion of specified research activities by DISCO, AbbVie will have the option to exclusively license selected programs for further development.
Cologne, Germany, November 19, 2026 - DISCO Pharmaceuticals (“DISCO”) today announced a strategic collaboration and option-to-license agreement with AbbVie to discover and develop novel AND-gated bispecific therapeutics for solid tumors with high unmet medical need.
Under the terms of the agreement, DISCO will receive $40 million in upfront payments and is eligible for up to $2.5 billion in option, development, and other milestone payments, plus tiered royalties on worldwide net sales.
“The collaboration with AbbVie represents an important opportunity to deliver the next generation of precision medicines to patients with difficult-to-treat solid tumors,” said Mark Manfredi, Ph.D., CEO of DISCO Pharmaceuticals. “Our AND-gated approach is designed to selectively target tumor cells while sparing healthy tissue, thus offering a potentially differentiated path in precision oncology. Our DISCOtech® platform’s unique ability to identify tumor-selective target pairs provides the foundation for therapies with the potential for a wider therapeutic window.”
“We look forward to working together with AbbVie towards the shared goal of creating transformative therapeutics for patients. This collaboration further underscores the potential of our differentiated platform and complements our portfolio of internal and partnered pipeline programs,” added Ajla Hrle, Ph.D., CBO of DISCO Pharmaceuticals.

About DISCO Pharmaceuticals

DISCO Pharmaceuticals is advancing a differentiated pipeline of highly selective, AND-gated therapeutics for hard-to-treat tumors. By uncovering novel cell surface target pairs through our disruptive DISCOtech® platform, we are designing AND-gated ADCs and T-cell engagers with the potential for unprecedented specificity and a broad therapeutic window to drive potent anti-tumor activity. DISCOtech® systematically maps cancer-specific cell-surface expression patterns and identifies target pairs that enable highly selective tumor recognition. Through simultaneous engagement of both targets, AND-gated therapeutics have the potential to broaden the addressable target space and reduce on-target off-tumor toxicity, a key limitation of solid tumor therapies. Our lead programs are progressing towards the clinic for small cell lung cancer and colorectal cancer. With each mapped surfaceome, we unlock new indication-specific and pan-tumor opportunities that can fundamentally shift the cancer treatment paradigm.

DISCO Pharmaceuticals Roopika Menon, PhD Email: press@discopharma.de

Media for DISCO Pharmaceuticals: Trophic Communications Anja Heuer or Stephanie May Phone: +49 171 1855682 Email: disco@trophic.eu

Frequently Asked Questions

What is the focus of the DISCO and AbbVie collaboration?

The collaboration aims to develop AND-gated bispecific therapeutics for solid tumors.

How much upfront payment will DISCO receive?

DISCO will receive $40 million in upfront payments.

What potential payments could DISCO earn from AbbVie?

DISCO is eligible for up to $2.5 billion in milestone payments.

What is the unique approach of DISCO's platform?

DISCO's platform identifies tumor-selective target pairs for precision oncology.

Last updated: Nov 19, 2026